Sectors
The property management software company, which counts Cisco among its investors, had raised $30m as of its last disclosed funding round.
Samsung acquired the mobile wallet developer LoopPay in February this year, providing exits to corporate backers Visa and Synchrony Financial.
The seed technology developer went public after raising more than $100m in funding from investors including BASF.
Johnson & Johnson and AbbVie bought a combined $55m of stock as the biopharmaceutical company, already listed in Europe, went public on Nasdaq.
Bank of Ireland Seed and Early Stage Fund plans to divest 25% of its portfolio in the next year, beginning with medical device developer NeoSurgical.
Novo, GlaxoSmithKline and Merck-backed molecular profiling platform HTG offered almost 3.6 million shares priced at $14 each.
Pet medicine developer Jaguar Animal Health, backed by Napo Pharmaceuticals, raised $20m after receiving $2.2m of venture funding.
Twitter revealed in its earnings report that it spent a combined $86.6m to acquire William Morris Endeavor-backed Niche and Periscope earlier this year.
Galapagos has increased the target for its upcoming IPO on Nasdaq to $230m, while $55m of the stock could be bought by AbbVie and Johnson & Johnson.
Novo Seeds, Lundbeck, Merck and Astellas all exited EpiTherapeutics after it was acquired by biopharmaceutical firm Gilead.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
